Cellular Responses to Cisplatin‐Induced DNA Damage

Abstract

Cisplatin is one of the most effective anticancer agents widely used in the treatment of solid tumors. It is generally considered as a cytotoxic drug which kills cancer cells by damaging DNA and inhibiting DNA synthesis. How cells respond to cisplatin‐induced DNA damage plays a critical role in deciding cisplatin sensitivity. Cisplatin‐induced DNA damage activates various signaling pathways to prevent or promote cell death. This paper summarizes our current understandings regarding the mechanisms by which cisplatin induces cell death and the bases of cisplatin resistance. We have discussed various steps, including the entry of cisplatin inside cells, DNA repair, drug detoxification, DNA damage response, and regulation of cisplatin‐induced apoptosis by protein kinases. An understanding of how various signaling pathways regulate cisplatin‐induced cell death should aid in the development of more effective therapeutic strategies for the treatment of cancer.

Cited by papers we hold 11

• Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis · 2023
  No notice
• Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment · 2021
  Corrected
• Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy · 2021
  No notice
• The Predictive Role of the Biomarker Kidney Molecule-1 (KIM-1) in Acute Kidney Injury (AKI) Cisplatin-Induced Nephrotoxicity · 2019
  No notice
• Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs · 2019
  No notice
• Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity · 2019
  No notice
• Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury · 2019
  No notice
• Cisplatin-Based Chemotherapy of Human Cancers. · 2019
  No notice
• Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi · 2018
  No notice
• Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. · 2016
  Not checked
• Baicalein, a Bioflavonoid, Prevents Cisplatin-Induced Acute Kidney Injury by Up-Regulating Antioxidant Defenses and Down-Regulating the MAPKs and NF-κB Pathways · 2015
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.